Affiliation:
1. From the National Cancer Institute of Canada–Clinical Trials Group, Kingston; University Health Network/Princess Margaret Hospital, Toronto; The Margaret & Charles Juravinski Cancer Centre (formerly known as Hamilton Regional Cancer Centre), Hamilton, Ontario; Hospital Universitario Doce de Octubre, Madrid, Spain; Centre Rene Gauducheau, Nantes, France; Klinikum Rechts Der III Medizinische Klinik, Munich; Krankenhaus Grobhansdorf der LVA, Grobhansdorf, Germany; Hôpital Jean Minjoz, Besançon, France;...
Abstract
Purpose To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non–small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs. Patients and Methods Chemotherapy-naive patients with stage IIIB/IV NSCLC, performance status (PS) 0 to 2, and adequate organ function were eligible. All patients received paclitaxel 200 mg/m2 plus carboplatin (area under the curve, 6 mg/mL-min) intravenously every 21 days for up to 8 cycles, and were randomly assigned to receive BMS-275291, 1,200 mg orally daily, or placebo until disease progression. The primary study end point was survival (OS); secondary end points included progression-free survival (PFS), response rates (RR), toxicity, and quality of life. Results From 2000 to 2002, 774 patients were randomly assigned. Pretreatment characteristics were well balanced between arms: median age, 61 years; male sex, 73%; stage IV, 79%; PS 0 to 1, 88%. Interim safety analysis revealed no survival advantage and increased toxicity in the experimental arm, and study treatment was stopped. Median OS, PFS and RR in the final analysis in the BMS-275291 arm were 8.6 months, 4.9 months, and 25.8% respectively, and in the control arm 9.2 months, 5.3 months, 33.7%. Toxicity was significantly higher in the BMS-275291 arm, including flu-like symptoms, rash, hypersensitivity reactions (8.6% v 2.4%), and febrile neutropenia (9.7% v 5.5%). Conclusion BMS-275291 added to chemotherapy increases toxicity and does not improve survival in advanced NSCLC.
Publisher
American Society of Clinical Oncology (ASCO)
Reference22 articles.
1. Estimating the world cancer burden: Globocan 2000
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy for non-small cell lung cancer [Cochrane Database System Review] . Oxford, England, Cochrane Library, CD002139, issue 2, 2000
3. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
4. Janecki-Delebecq T, Porte H, Zerimech F, et al: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 6:1086,2000-1092,
Cited by
164 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献